Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press2310.17650/1726-9776-2014-10-1-69-75REVIEWОБЗОРINTERMITTENT HORMONE THERAPY WITH ELIGARD IN PATIENTS WITH PROSTATE CANCERИНТЕРМИТТИРУЮЩАЯ ГОРМОНАЛЬНАЯ ТЕРАПИЯ ПРЕПАРАТОМ ЭЛИГАРД У БОЛЬНЫХ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫAlekseevB. Ya.АлексеевБ. Я.
Russian Federation
byalekseev@mail.ruKrasheninnikovA. A.КрашенинниковA. A.
Russian Federation
byalekseev@mail.ruNyushkoK. M.НюшкоК. М.
Russian Federation
byalekseev@mail.ruKalpinskyA. S.КалпинскийА. С.
Russian Federation
byalekseev@mail.ruKaprinA. D.КапринА. Д.
Russian Federation
byalekseev@mail.ruP.A. Herzen Moscow Oncology Research InstituteМНИОИ им. П. А. Герцена3003201410169752407201424072014https://oncourology.abvpress.ru/oncur/article/view/23

Prostate cancer (PC) is one of the most burning problems of modern urologic oncology, which is attributable to the fact that the incidence of this pathology remains high. Hormone therapy (HT) is a basic treatment in patients with metastatic PC. Intermittent HT (IHT) is an effective and safe method for hormonal exposure in PC patients, as supported by the results of many trials. IHT may be recommended in the therapy of patients with PC in different clinical situations, including in patients with distant metastases. Eligard is recognized to be an effective and safe medicament to treat this category of patients. Its injection formulation once three or six months is easy-to-use for IHT.

Рак предстательной железы (РПЖ) представляет собой одну из наиболее актуальных проблем современной онкоурологии, что объясняется сохраняющимися высокими показателями заболеваемости данной патологией. Гормональная терапия (ГТ) является основным методом лечения больных метастатическим РПЖ. Интермиттирующая гормональная терапия (ИГТ) –  эффективный и безопасный метод гормонального воздействия у больных РПЖ, что подтверждается результатами многих исследований. Проведение ИГТ может быть рекомендовано при терапии больных РПЖ в различных клинических ситуациях, в том числе у па-циентов с наличием отдаленных метастазов. Элигард признан удобным, эффективным и безопасным препаратом для лечения этой категории пациентов. Форма для инъекций 1 раз в 3 или 6 мес удобна для проведения ГТ в интермиттирующем режиме.

 

prostate cancerintermittent hormone therapyeligardleuprorelin acetateрак предстательной железыинтермиттирующая гормональная терапияэлигардлейпрорелина ацетат1. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2014.Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2014.2. Матвеев В.Б. Рак простаты. Врач 2005; (12):15–8.Матвеев В.Б. Рак простаты. Врач 2005; (12):15–8.3. Матвеев В.Б. Клиническая онкоурология. М., 2003; с. 525–570.Матвеев В.Б. Клиническая онкоурология. М., 2003; с. 525–570.4. Heidenreich A., Varga Z., Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2003;169 (3):1090.Heidenreich A., Varga Z., Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2003;169 (3):1090.5. Partin A. W., Kattan M. W., Subong E. N. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277 (18):1445–51.Partin A. W., Kattan M. W., Subong E. N. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277 (18):1445–51.6. Huggins C., Hoges C. V. Studies on prostate cancer. The effect of castration. Cancer Res 1941;385–402.Huggins C., Hoges C. V. Studies on prostate cancer. The effect of castration. Cancer Res 1941;385–402.7. Bayar D. P. Studies on prostate cancer and its treatment. 1977.Bayar D. P. Studies on prostate cancer and its treatment. 1977.8. Матвеев В. Б., Бабаев Э. Р. Влияние гормонотерапии на качество жизни больных распространенным раком предстательной железы. Вестн РНЦРР МЗ России 2011; (11):132–4.Матвеев В. Б., Бабаев Э. Р. Влияние гормонотерапии на качество жизни больных распространенным раком предстательной железы. Вестн РНЦРР МЗ России 2011; (11):132–4.9. Perez-Marrero R., Tyler R. C. A subcutaneous delivery system for the extended release of leupro lide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5 (2):447–57.Perez-Marrero R., Tyler R. C. A subcutaneous delivery system for the extended release of leupro lide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5 (2):447–57.10. Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 2003;61 (2 Suppl 1):25–31.Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 2003;61 (2 Suppl 1):25–31.11. Tunn U. W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology 2011;11:15. doi:10.1186 / 1471-2490-11-15.Tunn U. W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology 2011;11:15. doi:10.1186 / 1471-2490-11-15.12. Spitz A., Young J. M., Larsen L. et al. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prost Canc Prost Dis 2012;15:93–99; doi:10.1038 / pcan. 2011.50.Spitz A., Young J. M., Larsen L. et al. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prost Canc Prost Dis 2012;15:93–99; doi:10.1038 / pcan. 2011.50.13. Матвеев В.Б., Бабаев Э.Р. Сравнительный анализ результатов постоянной и интермиттирующей гормонотерапии распространенного рака предстательной железы. Онкоурология 2011; (1):51–6.Матвеев В.Б., Бабаев Э.Р. Сравнительный анализ результатов постоянной и интермиттирующей гормонотерапии распространенного рака предстательной железы. Онкоурология 2011; (1):51–6.14. Матвеев В. Б., Бабаев Э. Р. Факторы прогноза выживаемости больных распространенным раком предстательной железы, получающих гормонотерапию. Онкоурология 2011; (2):78–83.Матвеев В. Б., Бабаев Э. Р. Факторы прогноза выживаемости больных распространенным раком предстательной железы, получающих гормонотерапию. Онкоурология 2011; (2):78–83.15. Bruchovsky N., Rennie P. S., Coldman A. J. et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50(8):2275–82. http://www.ncbi.nlm.nih.gov / pubmed / 2317815Bruchovsky N., Rennie P. S., Coldman A. J. et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50(8):2275–82. http://www.ncbi.nlm.nih.gov / pubmed / 231781516. Miller K., Steiner U., Lingnau A. et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J ClinOncol 2007; Part1;25(18S).Miller K., Steiner U., Lingnau A. et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J ClinOncol 2007; Part1;25(18S).17. Calais da Silva F. E., Bono A. V., Whelan P. et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. EurUrol 2009;55(6):1269–77.Calais da Silva F. E., Bono A. V., Whelan P. et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. EurUrol 2009;55(6):1269–77.18. Irani J., Celhay O., Hubert J. et al. Association for Research in Urological Oncology. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. EurUrol 2008;54 (2):382–91.Irani J., Celhay O., Hubert J. et al. Association for Research in Urological Oncology. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. EurUrol 2008;54 (2):382–91.19. Verhagen P. C. M. S., Wissenburg L. D., Wildhagen M. F. et al. Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer. Eur Urol Suppl 2008;7 (3):206, abstr 541.Verhagen P. C. M. S., Wissenburg L. D., Wildhagen M. F. et al. Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer. Eur Urol Suppl 2008;7 (3):206, abstr 541.20. EAU Guidelines, 2013, p. 88.EAU Guidelines, 2013, p. 88.21. Pether M., Goldenberg S. L. Intermittent androgen suppression. BJU Int 2004;93 (3):258–61.22. Hussain M., Tangen C. M., Higano C. et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT- 0162). J Clin Oncol 2006;24 (24):3984–90.Pether M., Goldenberg S. L. Intermittent androgen suppression. BJU Int 2004;93 (3):258–61.22. Hussain M., Tangen C. M., Higano C. et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT- 0162). J Clin Oncol 2006;24 (24):3984–90.23. Lane T. M., Ansell W., Farrugia D. et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004;73 (2):117–22.Lane T. M., Ansell W., Farrugia D. et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004;73 (2):117–22.24. de Leval J., Boca P., Yousef E. et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1(3):163–71.de Leval J., Boca P., Yousef E. et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1(3):163–71.25. Hussain M., Tangen C. M., Higano C. S. et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of SWOG 9346 (INT-0162), an international phase III trial. J ClinOncol 2012;30 (suppl; abstr4).Hussain M., Tangen C. M., Higano C. S. et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of SWOG 9346 (INT-0162), an international phase III trial. J ClinOncol 2012;30 (suppl; abstr4).26. Prapotnich D., Cathelineau X., Rozet F. et al. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results. World J Urol 2009;27 (5):627–35.Prapotnich D., Cathelineau X., Rozet F. et al. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results. World J Urol 2009;27 (5):627–35.27. Opfermann K. J., Lai Z., Essenmacher L. et al. Intermittent hormone therapy in nonmetastatic prostate cancer. Clin Genitourin Cancer. 2006;5 (2):138–43.Opfermann K. J., Lai Z., Essenmacher L. et al. Intermittent hormone therapy in nonmetastatic prostate cancer. Clin Genitourin Cancer. 2006;5 (2):138–43.28. Kaneko Y., Maekawa S., Arakaki R. et al. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer. Hinyokika Kiyo 2006;52(4):259–64.Kaneko Y., Maekawa S., Arakaki R. et al. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer. Hinyokika Kiyo 2006;52(4):259–64.29. Pether M., Goldenberg S. L., Bhagirath K., Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 2003;10 (2):1809–14.Pether M., Goldenberg S. L., Bhagirath K., Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 2003;10 (2):1809–14.30. Salonen A. J., Taari K., Ala-Opas M. et al. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012;187 (6):2074–81.Salonen A. J., Taari K., Ala-Opas M. et al. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012;187 (6):2074–81.31. Tunn U. W., Kurek R., Renneberg H. et al. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35Suppl 1:27–31.Tunn U. W., Kurek R., Renneberg H. et al. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35Suppl 1:27–31.32. Irani J., Celhay O., Hubert J. et al. Association for Research in Urological Oncology. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomized study. Eur Urol 2008;54 (2):382–91. 33. Wolff J. M., Abrahamsson P. A., Irani J., Calais da Silva F. Is Intermittent Androgen Deprivation Therapy Beneficial For Advanced Prostate Cancer Patients? BJU Int 2014. doi: 10.1111 / bju. 12626.Irani J., Celhay O., Hubert J. et al. Association for Research in Urological Oncology. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomized study. Eur Urol 2008;54 (2):382–91. 33. Wolff J. M., Abrahamsson P. A., Irani J., Calais da Silva F. Is Intermittent Androgen Deprivation Therapy Beneficial For Advanced Prostate Cancer Patients? BJU Int 2014. doi: 10.1111 / bju. 12626.34. Salonen A. J., Viitanen J., Lundstedt S. et al. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol 2008;180 (3):915–9.Salonen A. J., Viitanen J., Lundstedt S. et al. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol 2008;180 (3):915–9.35. Hussain M. 1, Tangen C. M., Berry D. L. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368 (14):1314–25.Hussain M. 1, Tangen C. M., Berry D. L. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368 (14):1314–25.36. Crook J. M., O’Callaghan C. J., Ding K. et al. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR. 7 / SWOG JPR. 7 / CTSU JPR. 7 / UK Intercontinental Trial CRUKE / 01 / 013). J Clin Oncol2011;29 (suppl; abstr. 4514).Crook J. M., O’Callaghan C. J., Ding K. et al. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR. 7 / SWOG JPR. 7 / CTSU JPR. 7 / UK Intercontinental Trial CRUKE / 01 / 013). J Clin Oncol2011;29 (suppl; abstr. 4514).